BINEX Co. Ltd (053030) - Net Assets
Based on the latest financial reports, BINEX Co. Ltd (053030) has net assets worth ₩187.21 Billion KRW (≈ $126.87 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩304.35 Billion ≈ $206.25 Million USD) and total liabilities (₩117.14 Billion ≈ $79.38 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check BINEX Co. Ltd (053030) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩187.21 Billion |
| % of Total Assets | 61.51% |
| Annual Growth Rate | 13.96% |
| 5-Year Change | 4.84% |
| 10-Year Change | 25.99% |
| Growth Volatility | 36.28 |
BINEX Co. Ltd - Net Assets Trend (2004–2024)
This chart illustrates how BINEX Co. Ltd's net assets have evolved over time, based on quarterly financial data. See how many days can BINEX Co. Ltd fund operations to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for BINEX Co. Ltd (2004–2024)
The table below shows the annual net assets of BINEX Co. Ltd from 2004 to 2024. For live valuation and market cap data, see BINEX Co. Ltd market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩181.61 Billion ≈ $123.07 Million |
+0.16% |
| 2023-12-31 | ₩181.33 Billion ≈ $122.88 Million |
-5.37% |
| 2022-12-31 | ₩191.61 Billion ≈ $129.85 Million |
+6.20% |
| 2021-12-31 | ₩180.42 Billion ≈ $122.27 Million |
+4.16% |
| 2020-12-31 | ₩173.22 Billion ≈ $117.39 Million |
+7.93% |
| 2019-12-31 | ₩160.50 Billion ≈ $108.77 Million |
+7.40% |
| 2018-12-31 | ₩149.43 Billion ≈ $101.27 Million |
+16.06% |
| 2017-12-31 | ₩128.75 Billion ≈ $87.25 Million |
-8.39% |
| 2016-12-31 | ₩140.55 Billion ≈ $95.25 Million |
-2.49% |
| 2015-12-31 | ₩144.14 Billion ≈ $97.68 Million |
+47.92% |
| 2013-12-31 | ₩97.45 Billion ≈ $66.04 Million |
+6.04% |
| 2012-12-31 | ₩91.90 Billion ≈ $62.28 Million |
+30.20% |
| 2011-12-31 | ₩70.58 Billion ≈ $47.83 Million |
+104.60% |
| 2007-12-31 | ₩34.50 Billion ≈ $23.38 Million |
+8.12% |
| 2006-12-31 | ₩31.91 Billion ≈ $21.62 Million |
+10.08% |
| 2005-12-31 | ₩28.99 Billion ≈ $19.64 Million |
+117.64% |
| 2004-12-31 | ₩13.32 Billion ≈ $9.03 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to BINEX Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 278.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩20.71 Billion | 11.42% |
| Common Stock | ₩16.34 Billion | 9.01% |
| Other Components | ₩144.31 Billion | 79.57% |
| Total Equity | ₩181.36 Billion | 100.00% |
BINEX Co. Ltd Competitors by Market Cap
The table below lists competitors of BINEX Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Forth Smart Service Public Company Limited
BK:FSMART
|
$170.19 Million |
|
Agung Podomoro Land Tbk
JK:APLN
|
$170.25 Million |
|
Daehan Steel
KO:084010
|
$170.39 Million |
|
Siljansvik AB (publ)
ST:SIVI
|
$170.48 Million |
|
Cheng Fwa Industrial Ltd
TWO:5426
|
$170.12 Million |
|
MEDICLIN Aktiengesellschaft
XETRA:MED
|
$170.05 Million |
|
Castles Technology Co Ltd
TW:5258
|
$170.03 Million |
|
Hanjin Transportation Co. Ltd.
KO:002320
|
$170.01 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BINEX Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 181,307,526,610 to 181,361,189,120, a change of 53,662,510 (0.0%).
- Net loss of 35,070,820,730 reduced equity.
- Other factors increased equity by 35,124,483,240.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-35.07 Billion | -19.34% |
| Other Changes | ₩35.12 Billion | +19.37% |
| Total Change | ₩- | 0.03% |
Book Value vs Market Value Analysis
This analysis compares BINEX Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.37x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.76x to 1.37x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩4571.44 | ₩8050.00 | x |
| 2017-12-31 | ₩4186.34 | ₩8050.00 | x |
| 2018-12-31 | ₩4792.96 | ₩8050.00 | x |
| 2019-12-31 | ₩5146.11 | ₩8050.00 | x |
| 2020-12-31 | ₩5552.18 | ₩8050.00 | x |
| 2021-12-31 | ₩5834.14 | ₩8050.00 | x |
| 2022-12-31 | ₩6195.91 | ₩8050.00 | x |
| 2023-12-31 | ₩5862.90 | ₩8050.00 | x |
| 2024-12-31 | ₩5864.64 | ₩8050.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BINEX Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -19.34%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -26.97%
- • Asset Turnover: 0.47x
- • Equity Multiplier: 1.54x
- Recent ROE (-19.34%) is below the historical average (2.30%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 10.84% | 7.76% | 0.50x | 2.81x | ₩94.82 Million |
| 2005 | 9.18% | 8.16% | 0.71x | 1.60x | ₩-217.74 Million |
| 2006 | 10.30% | 8.62% | 0.75x | 1.59x | ₩85.71 Million |
| 2007 | 9.50% | 8.28% | 0.73x | 1.56x | ₩-157.04 Million |
| 2011 | 4.93% | 6.33% | 0.53x | 1.47x | ₩-3.48 Billion |
| 2013 | -4.20% | -7.10% | 0.47x | 1.26x | ₩-13.75 Billion |
| 2015 | -6.44% | -13.96% | 0.38x | 1.22x | ₩-23.70 Billion |
| 2016 | -2.14% | -3.71% | 0.46x | 1.26x | ₩-17.06 Billion |
| 2017 | -8.77% | -14.48% | 0.47x | 1.30x | ₩-24.17 Billion |
| 2018 | 4.24% | 6.09% | 0.55x | 1.27x | ₩-8.61 Billion |
| 2019 | 5.30% | 6.79% | 0.62x | 1.26x | ₩-7.55 Billion |
| 2020 | 3.70% | 4.82% | 0.49x | 1.56x | ₩-10.91 Billion |
| 2021 | 10.58% | 14.21% | 0.49x | 1.51x | ₩1.05 Billion |
| 2022 | 6.49% | 7.94% | 0.53x | 1.56x | ₩-6.72 Billion |
| 2023 | 2.58% | 3.02% | 0.60x | 1.42x | ₩-13.46 Billion |
| 2024 | -19.34% | -26.97% | 0.47x | 1.54x | ₩-53.21 Billion |
Industry Comparison
This section compares BINEX Co. Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.
Industry Context
- Industry: Pharmaceuticals
- Average net assets among peers: $97,254,266,943
- Average return on equity (ROE) among peers: 2.84%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BINEX Co. Ltd (053030) | ₩187.21 Billion | 10.84% | 0.63x | $170.14 Million |
| Sam Chun Dang Pharm. Co. Ltd (000250) | $148.52 Billion | 5.89% | 0.76x | $3.84 Billion |
| DongKoo Bio&Pharma Co. Ltd (006620) | $72.10 Billion | 6.34% | 0.45x | $26.72 Million |
| NatureCell Co.Ltd (007390) | $43.13 Billion | 5.18% | 0.23x | $1.10 Billion |
| Sam-A Pharm. Co. Ltd (009300) | $228.11 Billion | 5.67% | 0.08x | $57.08 Million |
| Kyung Dong Pharmaceutical Co. Ltd (011040) | $220.95 Billion | 9.27% | 0.14x | $83.52 Million |
| WooGene B&G Co. Ltd (018620) | $21.90 Billion | 1.61% | 0.93x | $44.78 Million |
| Oscotec Inc (039200) | $21.24 Billion | -18.33% | 0.91x | $739.87 Million |
| EstechPharma Co. Ltd (041910) | $102.72 Billion | 14.82% | 0.13x | $42.03 Million |
| Komipharm International Co. Ltd (041960) | $76.13 Billion | -8.60% | 0.75x | $329.88 Million |
| Eagle Veterinary Technology Co.Ltd (044960) | $37.74 Billion | 6.52% | 0.28x | $27.07 Million |
About BINEX Co. Ltd
BINEX Co., Ltd. operates as a pharmaceutical company in South Korea. It offers bisroot products; GI tract and antispasmodic, and antiulcer agents; NSAIDs; cardiovascular and urology products; hepatic protectors; ointments and creams; ophthalmic solutions; CNS agents; digestive products; constipation and blood circulation products; antibiotic and antifungal agents; cough and cold remedy products; … Read more